March 13, 2019 09:01 AM EDTUpdated March 14, 09:36 AM

Emma Walmsley earns £1M pay rise in her first full year at GSK's helm — but £5.9M package still trails other Big Pharma CEOs

Amber Tong

Emma Walmsley’s £1 million ($1.3 million) pay raise in 2018 might have made her the highest-paid women on the FTSE 100, but the GlaxoSmithKline CEO’s compensation package still trails her peers in Big Pharma corner offices.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

Emma Walmsley earns £1M pay rise in her first full year at GSK's helm — but £5.9M package still trails other Big Pharma CEOs

Amber Tong

Sign up to read this article for free.

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

The Biden administration wants Medicare and Medicaid to cover GLP-1s. Will the Trump White House allow it?

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Food allergy biotech Alladapt closes after Phase 3 talks with FDA

Soleno’s rare pediatric disease drug faces PDUFA delay by three months

Em­ma Walm­s­ley earns £1M pay rise in her first full year at GSK's helm — but £5.9M pack­age still trails oth­er Big Phar­ma CEOs

Amber Tong

Sign up to read this article for free.

more like this

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Food al­ler­gy biotech Al­ladapt clos­es af­ter Phase 3 talks with FDA

Soleno’s rare pe­di­atric dis­ease drug faces PDU­FA de­lay by three months

Emma Walmsley earns £1M pay rise in her first full year at GSK's helm — but £5.9M package still trails other Big Pharma CEOs

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

The Biden administration wants Medicare and Medicaid to cover GLP-1s. Will the Trump White House allow it?

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Food allergy biotech Alladapt closes after Phase 3 talks with FDA

Soleno’s rare pediatric disease drug faces PDUFA delay by three months